抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展

doi:10.11904/j.issn.1002-3070.2021.02.015

Abstract

Abstract: Most patients with head and neck squamous cell carcinoma(HNSCC)are in advanced stage when they are diagnosed.The recurrence rate and metastasis rate of traditional regimen are about 60% and 30%,respectively.However,the treatment of recurrent and metastatic HNSCC(R/M HNSCC)is limited,and the long-term survival rate needs to be improved.The emergence of immune checkpoint inhibitors can effectively improve the overall survival of these patients,and bring hope for HNSCC patients.This paper summarizes the research progress of programmed death protein-1(PD-1),programmed death ligand-1(PD-L1)and cytotoxic T lymphocyte associated antigen 4(CTLA-4)inhibitors and their combination therapy in HNSCC in recent years,hoping to provide a new treatment for clinicians.

Key words: PD-1;PD-L1;CTLA-4;Immunotherapy;Head and neck squamous cell carcinoma

CLC Number:

R739.81

WANG Mingming, CHEN Xiaopin. Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma[J]. Journal of Practical Oncology, 2021, 35(2): 179-183.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.02.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I2/179

References

1 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:Sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
2 Vanoijen MG,Slootweg PJ.Oral field cancerization:carcinogen-induced independent events or micrometastatic deposits[J].Cancer Epidemiol Biomarkers Prev,2000,9(3):249-256.
3 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
4 Pan R,Zhu M,Yu C,et al.Cancer incidence and mortality:a cohort study in China,2008-2013[J].Int J Cancer,2017,141(7):1315-1323.
5 Nwizu T,Adelstein D.Pharmacotherapy of head and neck cancer[J].Expert Opin Pharmacother,2015,16(16):2409-2422.
6 Seiwert TY,Cohen EE.State-of-the-art management of locally advanced head and neck cancer[J].Br J Cancer,2005,92(8):1341-1348.
7 Pulte D,Brenner H.Changes in survival in head and neck cancers in the late 20th and early 21st century:a period analysis[J].Oncologist,2010,15(9):994-1001.
8 Marur S,Forastiere AA.Head and neck cancer:changing epidemiology,diagnosis,and treatment[J].Mayo Clin Proc,2008,83(4):489-501.
9 Napolitano M,Schipilliti FM,Trudu L,et al.Immunotherapy in head and neck cancer:The great challenge of patient selection[J].Crit Rev Oncol Hematol,2019,144:102829.
10 Pignon JP,le Maître A,Maillard E,et al.Meta-analysis of chemotherapy in head and neck cancer(MACH-NC):an update on 93 randomised trials and 17346 patients[J].Radiother Oncol,2009,92(1):4-14.
11 Bourhis J,Le Maître A,Baujat B,et al.Individual patients' data meta-analyses in head and neck cancer[J].Curr Opin Oncol,2007,19(3):188-194.
12 Posner MR,Hershock DM,Blajman CR,et al.Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J].N Engl J Med,2007,357(17):1705-1715.
13 Brockstein B,Haraf DJ,Rademaker AW,et al.Patterns of failure,prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy:a 9-year,337-patient,multi-institutional experience[J].Ann Oncol,2004,15(8):1179-1186.
14 Sunshine J,Taube JM.PD-1/PD-L1 inhibitors[J].Curr Opin Pharmacol,2015,23:32-38.
15 Krummel MF,Allison JP.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation[J].J Exp Med,1995,182(2):459-465.
16 Ferris RL,Blumenschein GJ,Fayette J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J].N Engl J Med,2016,375(19):1856-1867.
17 Ferris RL,Blumenschein G,Fayette J,et al.Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck:2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J].Oral Oncol,2018,81:45-51.
18 曾玉兰,刘洋洋,梁金燕,等.免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J].实用肿瘤学杂志,2017,31(4):353-358.
19 Ferris RL,Gillison ML,Harris J,et al.Safety evaluation of nivolumab(Nivo)concomitant with cetuximab-radiotherapy for intermediate(IR)and high-risk(HR)local-regionally advanced head and neck squamous cell carcinoma(HNSCC):RTOG 3504[J].J Clin Oncol,2018,36(15-suppl):6010.
20 Mcbride SM,Sherman EJ,Tsai CJ,et al.A phase II randomized trial of nivolumab with stereotactic body radiotherapy(SBRT)versus nivolumab alone in metastatic(M1)head and neck squamous cell carcinoma(HNSCC)[J].J Clin Oncol,2018,36(15 suppl):6009.
21 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicentre,phase 1b trial[J].Lancet,2016,17(7):956-965.
22 Chow LQM,Haddad R,Gupta S,et al.Antitumor activity of pembrolizumab in biomarker-Unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma:results from the phase Ib KEYNOTE-012 expansion cohort[J].J Clin Oncol,2016,34(32):3838-3845.
23 Cohen EEW,Soulières D,Le Tourneau C,et al.Pembrolizumab versus methotrexate,docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma(KEYNOTE-040):a randomised,open-label,phase 3 study[J].Lancet,2019,393(10167):156-167.
24 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
25 Powell SF,Gitau MM,Sumey CJ,et al.Safety of pembrolizumab with chemoradiation(CRT)in locally advanced squamous cell carcinoma of the head and neck(LA-SCCHN)[J].J Clin Oncol,2017,35(15 suppl):6011.
26 Sun XS,Sire C,Tao Y,et al.A phase II randomized trial of pembrolizumab versus cetuximab,concomitant with radiotherapy(RT)in locally advanced(LA)squamous cell carcinoma of the head and neck(SCCHN):first results of the GORTEC 2015-01 "PembroRad" trial[J].J Clin Oncol,2018,36(15 suppl):6018.
27 Wise-Draper TM,Old MO,Worden FP,et al.Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma[J].J Clin Oncol,2018,36(15 suppl):6017.
28 Wang F,Wei X,Feng JF,et al.Recombinant humanized anti-PD-1 monoclonal antibody(JS001)in patients with refractory/metastatic nasopharyngeal carcinoma:interim results of an open-label phase II clinical study[J].J Clin Oncol,2019,37(15 suppl):6017.
29 Fang W,Yang Y,Ma Y,et al.Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm,phase 1 trials[J].Lancet Oncol,2018,19(10):1338-1350.
30 Zandberg DP,Algazi AP,Jimeno A,et al.Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma:Results from a single-arm,phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy[J].Eur J Cancer,2019,107:142-152.
31 Siu LL,Even C,Mesía R,et al.Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/Negative recurrent or metastatic HNSCC[J].JAMA Oncol,2019,5(2):195.
32 Licitra LF,Haddad RI,Even C,et al.EAGLE:A phase 3,randomized,open-label study of durvalumab(D)with or without tremelimumab(T)in patients(pts)with recurrent or metastatic head and neck squamous cell carcinoma(R/M HNSCC)[J].J Clin Oncol,2019,37(15 suppl):6012.
33 Heery CR,O'Sullivan-Coyne G,Madan RA,et al.Avelumab for metastatic or locally advanced previously treated solid tumours(JAVELIN Solid Tumor):a phase 1a,multicohort,dose-escalation trial[J].Lancet Oncol,2017,18(5):587-598.
34 Elbers JBW,Al-Mamgani A,Tesseslaar MET,et al.Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma:results from a phase-I trial[J].Radiother Oncol,2020,142:79-84.
35 Colevas AD,Bahleda R,Braiteh F,et al.Safety and clinical activity of atezolizumab in head and neck cancer:results from a phase I trial[J].Ann Oncol,2018,29(11):2247-2253.

Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics

Comments